Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Epidermal Growth Factor Receptor 2 (HER2)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05350917
What this trial is testing

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

Who this might be right for
HER2-positive or Mutated Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University 20
Testing effectiveness (Phase 2)Looking for participantsNCT05837455
What this trial is testing

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Who this might be right for
Breast CancerCancer of the Breast
Washington University School of Medicine 81
Testing effectiveness (Phase 2)UnknownNCT02396108
What this trial is testing

Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
National University Hospital, Singapore 55
Testing effectiveness (Phase 2)Study completedNCT00258960
What this trial is testing

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 49
Testing effectiveness (Phase 2)WithdrawnNCT03644589
What this trial is testing

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMetastatic Breast Cancer+3 more
University of Washington
Not applicableStudy completedNCT07223476
What this trial is testing

Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,926
Not applicableNot Yet RecruitingNCT07670182
What this trial is testing

The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer

Who this might be right for
Patients With Low HER2 Expression (IHC 1+ or IHC 2+/ISH-) and HER2 IHC 0 Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 100
Large-scale testing (Phase 3)Study completedNCT03726879
What this trial is testing

Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 454
Large-scale testing (Phase 3)Study completedNCT01104935
What this trial is testing

National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]

Who this might be right for
Breast Cancer
Comprehensive Support Project for Oncology Research 275
Not applicableStudy completedNCT06636591
What this trial is testing

Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer

Who this might be right for
Breast Cancer FemaleHER2-negative Breast Cancer
Fudan University 14
Testing effectiveness (Phase 2)Study completedNCT01275859
What this trial is testing

Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Asan Medical Center 25
Testing effectiveness (Phase 2)Looking for participantsNCT07483307
What this trial is testing

The Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerHER2 Negative Breast Carcinoma+2 more
Memorial Sloan Kettering Cancer Center 176
Testing effectiveness (Phase 2)Active Not RecruitingNCT03377387
What this trial is testing

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 34
Early research (Phase 1)Study completedNCT04572295
What this trial is testing

E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Eisai Co., Ltd. 51
Early research (Phase 1)Study completedNCT00250419
What this trial is testing

V930 First in Man (FIM) Study (V930-002)(COMPLETED)

Who this might be right for
Cancers Expressing HER-2 and/or CEA
Merck Sharp & Dohme LLC 26
Large-scale testing (Phase 3)Enrolling By InvitationNCT05645536
What this trial is testing

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Who this might be right for
Breast Cancer
Tolmar Inc. 250
Early research (Phase 1)Study completedNCT00372424
What this trial is testing

Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Who this might be right for
Breast Cancer
Pfizer 26
Testing effectiveness (Phase 2)Study completedNCT02102490
What this trial is testing

Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 132
Not applicableStudy completedNCT07072013
What this trial is testing

An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,937
Testing effectiveness (Phase 2)Study completedNCT00463788
What this trial is testing

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

Who this might be right for
Breast Neoplasm
Merck KGaA, Darmstadt, Germany 181
Next Page